Clipping of news on Brazilian Culture, Law and Citizenship
 


Health

Post-market surveillance is a strategy for safer medicines

16/11/2012

This article was translated by an automatic translation system, and was therefore not reviewed by people.

 


 


Ended on Wednesday (14/11), the 35th Annual Meeting of the participating countries of the Programme for International Drug Monitoring the World Health Organization (WHO). This was the first time the meeting took place in Brazil.

During the closure, the CEO of ANVISA, Dirceu Barbano, highlighted the need to change the current paradigm of quality control of drugs. According to him, countries have been quite strict at the time the product enters the market, but it is necessary to go back efforts for surveillance of drugs already in use by the population, the so-called post-market. "Every year we are convinced that we can only extend our work if we rely on the capacity already developed by other countries," concluded Barbano.

The meeting is an important forum for discussion about drug safety and is coordinated by the Center for International Drug Monitoring in Uppsala (UMC), the World Health Organization (WHO), located in the city of Uppsala, Sweden.

Highlights

The need to encourage the reporting of effects and adverse reactions by patients and drug users was one of the aspects highlighted during the meeting. For participants, it is essential to create tools to facilitate the notification by the population itself, which may allow a significant improvement in the ability of countries to identify problems in products already launched in the market.

Another point discussed by enough countries was the need to improve the tools for the exchange of information between authorities in global health. According to the head of the Center for Management of the National Reporting and Investigation Anvisa, Maria Eugenia Cury, the drug trade is global, which requires action in all countries. She said the rapid identification of adverse events and reactions is essential for countries around the world can make the necessary recommendations in relation to their populations.

The 35 ˚ Annual Meeting of the countries participating in the Programme for International Drug Monitoring the WHO 49 countries gathered for four days in Brasilia.

What is pharmacovigilance

Pharmacovigilance is the branch of health monitoring and investigating adverse reactions to drugs already on the market. Their work aims to identify unknown facts about drugs.

This work is of great importance for health, it is not always the studies prior to entry of a drug on the market are able to identify all the factors related to that product. While large clinical trials are performed, on average, five thousand patients, certain information is only identified when this product goes to the market and is now used by thousands and even millions of people.

Read more: Global strategy for the safe use of medicines



Source: Anvisa

Our news are removed entirely from the sites of our partners. For this reason, we can not change their content even in cases of typos.

This article was translated by an automatic translation system, and was therefore not reviewed by people.

Important:
The JurisWay site does not interfere in the work provided by doctrine, why only reflect the opinions, ideas and concepts of their authors.


  Subjects list
 
  Copyright (c) 2006-2009. JurisWay - All rights reserved.